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Abstract
Purpose—Chemotherapy-related amenorrhea (CRA) is associated with infertility and 
menopausal symptoms. Learning how frequently paclitaxel and trastuzumab cause amenorrhea is 
important. Most other adjuvant breast cancer therapies induce CRA in approximately 50% of all 
premenopausal recipients [1].
Methods—410 patients enrolled on the APT Trial, a single-arm phase 2 adjuvant study of 12 
weeks of paclitaxel and trastuzumab followed by nine months of trastuzumab monotherapy. 
Eligible patients had ≤3cm node-negative HER2+ breast cancers. Premenopausal enrollees were 
asked to complete menstrual surveys every 3-12 months for 72 months. Women who responded to 
at least one survey at least 15 months after chemotherapy initiation (and who did not undergo 
hysterectomy and/or bilateral oophorectomy or receive ovarian suppressing medications prior to 
15 months) were included in this analysis. A participant was defined as having amenorrhea in 
follow-up if her self-reported last menstrual period at last follow-up was greater than 12 months 
prior to the survey.
Results—Among the 64 women in the evaluable population (median age at study entry 44 years, 
range 27-52 years), the median time between chemotherapy initiation and last menstrual survey 
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was 51 months (range 16-79). 18 of 64 women (28%, 95% CI 18-41%) were amenorrheic at that 
time point.
Conclusions—Amenorrhea rates among premenopausal women treated with adjuvant paclitaxel 
and trastuzumab for early stage breast cancer appear lower than those seen historically with 
standard alkylator-based breast cancer regimens. Future studies are needed to understand the 
impact of this regimen on related issues of fertility and menopausal symptoms.
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Introduction
Approximately one quarter of all breast cancers diagnosed in the United States occur in 
premenopausal women. Standard chemotherapies for breast cancer may damage the ovaries, 
causing temporary or permanent loss of menses (chemotherapy-related amenorrhea) in many 
young women. Chemotherapy-related amenorrhea (CRA) is associated with reduced ovarian 
function and fertility. This is a concern for women who wish to conceive and bear biological 
children after their breast cancer treatments are finished. Importantly, CRA also is associated 
with improved prognosis in women with estrogen receptor-positive (ER+) tumors [2,3]. 
Thus, when premenopausal women are deciding between multiple options for chemotherapy 
for early stage breast cancer, understanding the likelihood of CRA may contribute to 
individualized clinical recommendations. Specifically, knowledge of a young woman's 
likelihood of experiencing CRA could guide decision-making about breast cancer treatments 
(e.g., whether to receive chemotherapy for a small estimated reduction in risk of recurrence) 
and fertility preservation techniques (e.g., whether to undergo oocyte or embryo 
cryopreservation prior to chemotherapy). Older age and higher doses of alkylating agents are 
known to be associated with more CRA [4,5], but the risk of CRA with certain 
chemotherapy regimens is less well established.
Doxorubicin-cyclophosphamide followed by paclitaxel-trastuzumab, a common adjuvant 
regimen for Her2-positive breast cancer, has been shown to induce CRA in approximately 
50% of all premenopausal recipients [1]. Although data are mixed and inconclusive [6-9,4], 
many studies show that rates of amenorrhea differ only minimally if at all with or without a 
taxane or with or without trastuzumab after anthracycline-based chemotherapy [10,11,1]. No 
study to date has reported on the risk of CRA after a taxane in the absence of other 
gonadotoxic treatments. Rates of CRA were examined in a phase 2 single-arm trial of 
adjuvant paclitaxel-trastuzumab (APT trial) [12].
Methods
410 patients were enrolled on a single-arm phase 2 adjuvant chemotherapy study of 12 
weeks of paclitaxel-trastuzumab followed by nine months of trastuzumab monotherapy for 
patients with ≤3cm of node-negative Her2+ breast cancer (APT Trial). The study was 
activated on October 9, 2007 and closed to enrollment on September 3, 2010. Menses 
assessment data were extracted on November 5, 2014.
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All participants enrolled in the APT Trial were asked to complete menstrual surveys at 
baseline. Each participant was asked 1) whether she menstruated in the past 6 months; 2) 
menstrual frequency if she menstruated in the past 6 months; 3) the first day of her last 
menstrual period; 4) whether she considered herself pre-menopausal at that time; 5) whether 
she took any hormonal agents in the past 6 months. Participants were deemed 
premenopausal at baseline if they met all of the following criteria: 1) age less than 55 years; 
2) at least one menstrual period in the prior 6 months with menstrual frequency at least every 
2 months; and 3) considered themselves pre-menopausal at baseline. If a participant was 
deemed premenopausal at baseline by these three criteria, she was asked to complete 
menstrual surveys at 12 weeks as well as at 6, 12, 18, 24, 30, 36, 48, 60 and 72 months after 
initiation of protocol treatment. In the current paper, we do not report on the 12 week, 6 
month, or 12 month surveys because the loss of menses during and soon after chemotherapy 
is very common and does not necessarily imply poor long-term ovarian function (which is 
more relevant for future fertility). The first survey we report on is from approximately 18 
months after chemotherapy initiation because amenorrhea for the one year after 
chemotherapy ended has been the most common endpoint in other studies of chemotherapy-
related amenorrhea after standard breast cancer regimens [13]. However, later time points 
were also considered important because menstruation later may be more reflective of long-
term ovarian function and fertility potential.
A participant was included in this analysis if she was premenopausal at baseline, responded 
to at least one follow-up menstrual survey at least 15 months after her first dose of 
chemotherapy, did not undergo surgical menopause or receive ovarian suppression before 15 
months after chemotherapy initiation, was not diagnosed with disease recurrence or new 
primary cancer within 15 months after starting chemotherapy, and did not withdraw study 
consent within 15 months after starting chemotherapy.
For each participant, the last informative follow-up survey (i.e., the latest survey on which 
the menstrual data were thought to reflect post-treatment ovarian function) was used to 
determine the amenorrhea status after treatment, with the definition of “informative” 
explained in the below paragraph. If a participant underwent surgically-induced menopause 
or received ovarian suppressing medication, and the date of that surgery or initial dose of 
medication was more than 15 months after her first dose of chemotherapy, the last survey 
prior to ovarian surgery date or initiation of ovarian suppression was used. If a participant 
was diagnosed with disease recurrence or a new primary cancer at least 15 months after her 
first dose of chemotherapy, the last survey prior to the diagnosis date was used. If participant 
withdrew study consent at least 15 months after her first dose of chemotherapy, the last 
survey prior to the date she withdrew study consent was used. If participant experienced 
more than one of the events listed above, the event that occurred earliest was used to 
determine which follow-up survey would be used, and surveys at protocol-specified time 
points after the event date were deemed “not applicable”. When a survey was missed prior to 
the last informative survey, the menstrual status at the missed time point was deemed “not 
assessed.” Participants were categorized as amenorrheic if the last menstrual period (LMP) 
on the most recent informative follow-up survey was more than 12 months prior.
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Descriptive statistics were used to summarize patients' baseline characteristics and menstrual 
status at last informative follow-up survey. Follow-up survey completion status and 
participants' menstrual status at each protocol-specified time point were tabulated. The 
association between a patient's demographic/treatment characteristics and menstrual status at 
the time of her last informative menstrual survey was assessed using two sample t-tests for 
continous variables [age and body mass index (BMI)], and Fisher's exact tests for categorical 
variables (race and whether or not she was taking endocrine therapy at the time of her last 
informative survey). A logarithmic transformation was used for normalization of the BMI 
data.
Results
Four hundred and ten patients enrolled in the APT trial, and 406 patients started protocol 
therapy. Seventy six participants (19%) were considered premenopausal at enrollment. 
Participants were not considered premenopausal for the following reasons (participants were 
often excluded for more than one reason): 205 (50%) participants were age ≥55 at 
enrollment; 253 (62%) participants reported no menses in the past 6 months; 15 (4%) 
participants had had menses but less often than every 2 months in the past 6 months; 12 
(3%) participants reported that they had menstruated in the past 6 months but did not know 
their menstrual frequency; 174 (43%) participants' LMP dates were unknown; 132 (33%) 
participants considered themselves not premenopausal or were unsure about their menstrual 
status. Among the participants who were premenopausal at enrollment, 10 underwent 
surgically-induced menopause within 15 months after their first dose of chemotherapy, and 2 
were lost to follow-up for menstrual status (Figure 1). No participants received ovarian 
function suppression before 15 months after their first dose of chemotherapy. Sixty four 
participants were included in the analysis (Table 1).
Among these 64 women, median age at study entry was 44 (range 27-52). The median time 
between first dose of chemotherapy and the last informative menstrual survey was 51 
months (range 16-79) and did not vary by menstrual status. During follow-up, 5 (8%) of the 
64 went on to experience surgically-induced menopause, 3 (5%) received ovarian suppresing 
medication, 1 (2%) was diagnosed ipsilateral recurrence, 3 (5%) were diagnosed with new 
primary contralateral breast cancers, and 2 (3%) withdrew study consent. Surveys after those 
events were not considered to be informative.
Four (6%) of the 64 participants had discontinued protocol treatment during either the 
chemotherapy portion or the trastuzumab monotherapy portion. Three discontinued protocol 
treatment for a protocol-specified toxicity (grade 3 ALT/SGPT elevation at 4 weeks, grade 2 
sensory neuropathy at 6 weeks, and grade 2 dyspnea at 28 weeks), and one discontinued due 
to another toxicity (grade 2 anxiety at 24 weeks). All of these participants were included in 
our analyses of amenorrhea rates.
Of the 64, 18 (28%, 95% CI 18-41%) were amenorrheic (had not menstruated for at least 12 
months) and 46 (72%, 95% CI 59-82%) were not amenorrheic (had menstruated within the 
prior 12 months) at the time of their last available menstrual survey. At the time of that 
survey, 39 reported that they were receiving endocrine therapy (34 tamoxifen, 5 aromatase 
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inhibitor), and 25 reported that they were not receiving endocrine therapy. Eighty-two 
percent of respondents to the 24 month survey and 73% of respondents to the 36 month 
survey were non-amenorrheic at that time (Figure 2). Data are missing in 3-19% of eligible 
participants at each time point over 72 months of follow-up. The menstrual status at 
protocol-specified time points are tabulated in Table 2.
The median age at study entry for participants who were non-amenorrheic at the time of the 
last informative menstrual survey was 42 years (range:27-49), and 49 years (range: 40-52) 
for participants who were amenorrheric. Older participants were more likely to be 
amenorrheic after protocol therapy (p<0.001), as were patients receiving endocrine therapy 
(p=0.03) (Table 3). Seventy eight percent of participants who were amenorrheic at the time 
of last available menstrual survey were aged 45 or above. In contrast, only 33% of 
participants who were not amenorrheic at the time of last available menstrual survey were 45 
years or older (Table 3). Of the 11 patients who were diagnosed at or under age 40, only a 
single patient (9%) was amenorrheic at the time of last available menstrual survey (Table 3). 
Race and body mass index were not found to be associated with amenorrhea after paclitaxel-
trastuzumab (p= 0.82 and 0.23, respectively). It was not possible to assess for an association 
between amenorrhea and prognosis because there have been so few recurrences on this trial.
Conclusions
Among premenopausal women who received adjuvant paclitaxel and trastuzumab (median 
age 44 at chemotherapy initiation), we found a 28% (95% CI 18-41%) rate of long-term 
(median 4 years after chemotherapy initiation) amenorrhea. This is lower than the 
approximately 50% amenorrhea rate 36 months after a breast cancer diagnosis in 
premenopausal women aged 40 or older (median age 46) who received no adjuvant therapy 
on IBCSG VIII [14], and also lower than would be expected with standard adjuvant 
cytotoxic breast cancer regimens, after which the majority of premenopausal women 
experience prolonged amenorrhea [15,16,3]. For example, Petrek and colleagues found that 
approximately 55% of women who received anthracycline-based and/or alkylating agent-
based chemotherapy for early stage breast cancer before the age of 45 were amenorrheic 
three years after diagnosis, and approximately 65% were amenorrheic at five years. 
Amongst those diagnosed between age 40-45 in that study, the CRA rate was approximately 
80% at three years, while the rate in those aged 35-39 was approximately 50%, and the rate 
in those under 35 was only 10% [4].
As in studies of other chemotherapy regimens, CRA appears highly age-dependent after 
therapy with paclitaxel and trastuzumab, consistent with evidence that age-associated 
declines in ovarian reserve increase the likelihood of prolonged loss of ovarian function after 
chemotherapy [17]. Not suprisingly given previous research showing that tamoxifen 
increases the rate of amenorrhea after chemotherapy [13,4,18,19], we also found that 
endocrine therapy use was associated with amenorrhea. The limited number of 
premenopausal patients on this study did not allow a precise estimate of the association 
between race and body mass index and CRA, and was underpowered to detect differences as 
statistically significant.
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This study is limited by incomplete data collection (not all patients responded to menstrual 
surveys at all time points) and a single-arm design. A larger study with more complete 
menstrual follow-up and with a matched control group will be needed to confirm and clarify 
these findings.
Nevertheless, to our knowledge, this study is the first that documents rates of amenorrhea 
after paclitaxel with trastuzumab alone. We believe that the relatively low amenorrhea rates 
seen here in women treated in their mid-40s suggest that this regimen is relatively sparing of 
ovarian function. Trastuzumab is not believed to cause CRA [1], and these results suggest 
that it is possible that paclitaxel as a single agent has only a limited effect if any (these rates 
of amenorrhea may not actually be any higher than would be expected in the general 
population of women at a median age of 48 who did not receive chemotherapy). These data 
may increase the appeal of this approach (and of other regimens that avoid anthracyclines 
and alkylating agents) for young women who prioritize future fertility. On the other hand, 
these data may decrease the appeal of this regimen for those who are hoping to reap a 
potential recurrence reduction benefit from CRA [20]. It will therefore be important to study 
how these low CRA rates after paclitaxel and trastuzumab may impact related issues of 
fertility, menopausal symptoms, and prognosis in young women. CRA is known to be 
associated with worse menopausal symptoms (e.g., hot flashes) [21,22], and reduced fertility 
[23], both of which may impair quality of life. While it is possible that risk of recurrence 
may be reduced by CRA after paclitaxel-trastuzumab [20], the event rate in the APT trial 
was so low (98.7% of participants were disease free at 3 years) that the associated absolute 
benefit would likely be very minimal.
Moving forward with new clinical trials of novel adjuvant and neoadjuvant breast cancer 
regimens (e.g., when a platinum is added to standard therapy, or when trastuzumab-
emtansine is studied as an alternative treatment for Her2-positive disease), it will be critical 
to evaluate rates of CRA to facilitate optimal counseling of young women about the risks 
and benefits of various treatment options. In order to minimize unnecessary burden on 
patients and cost, learning which chemotherapy regimens are not likely to cause prolonged 
CRA may be relevant to the understanding of which patients will be most likely to benefit 
from GNRH agonist injections (which only have been shown to improve prognoses in 
women who would otherwise be menstruating after chemotherapy).[20]
In conclusion, amenorrhea rates among premenopausal women treated with adjuvant 
paclitaxel and trastuzumab for early stage breast cancer appear lower than would be 
expected with standard adjuvant cytoxic breast cancer regimens. These preliminary findings 
warrant additional study.
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Figure 1. Flow diagram of participants
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Figure 2. Menstrual status at protocol specified time points
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Table 1
Patient Characteristics
Evaluable premenopausal patients (N=64) All patients (N=406)
N % N %
Age at study entry (years)
 ≤40 years 11 17 21 5
 41-45 years 24 38 52 13
 >45 years 29 45 333 82
Race
 White 59 92 351 86
 Black 1 2 28 7
 Asian 2 3 11 3
 Other 2 3 16 4
Body Mass Index (kg/m2) at study entry
<25 41 64 180 44
25-29.9 18 28 129 32
30+ 5 8 97 24
Size of primary tumor
T1mi ≤ 0.1cm 3 5 9 2
T1a 0.1-≤0.5cm 14 22 68 17
T1b 0.5- ≤1.0cm 22 34 124 31
T1c 1.0- ≤2.0cm 22 34 169 42
T2 2.0- ≤3.0cm 3 5 36 9
Histologic grade
I - Well differentiated 9 14 44 11
II - Moderately differentiated 27 42 131 32
III - Poorly differentiated 28 44 228 56
Unknown 0 0 3 1
ER status
Positive 23 36 260 64
Negative 40 63 141 35
Borderline 1 2 5 1
PR status
Positive 27 42 201 50
Negative 36 56 196 48
Borderline 1 2 8 2
Unknown 0 0 1 <1
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Table 3
Clinical characteristics of amenorrheic and non-amenorrheic participants
Amenorrheic (N= 18) Non-amenorrheic (N= 46)
N % N %
Age at study entry (years)
 ≤40 years 1 6 10 22
 41-45 years 3 17 21 46
 >45 years 14 78 15 33
Race
 White 17 94 42 91
 Black 0 0 1 2
 Asian 1 6 1 2
 Other 0 0 2 4
Body Mass Index (kg/m2) at study entry
<25 7 39 34 74
25-29.9 8 44 10 22
30+ 3 17 2 4
Taking endocrine therapy at last menstrual survey
Yes 15 83 24 52
No 3 17 22 48
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